05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts used as ingredients for nutritional supplements for dietary and health applications; dietetic foods, beverages and substances adapted for medical use; nutritional additives for medical purposes; medical and pharmaceutical preparations.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts used as ingredients for nutritional supplements for dietary and health applications; dietetic foods, beverages and substances adapted for medical use; nutritional additives for medical purposes; medical and pharmaceutical preparations
3.
WITHANIA SOMNIFERA COMPOSITION FOR COGNITIVE HEALTH
The present invention relates to an oral composition of Withania extract as or its salts and/or in combination with total Withanolides comprising Withanolide Glycosides (Withanoside IV and Withanoside V/VI) and Withanolide aglycones (Withanolide A, Withanolide B, Withaferin-A and 12- deoxy withastramonolide) and/or its salts. The present invention is also related to the process of preparation of the oral composition Withania somnifera and at least one pharmaceutically and/or nutraceutically acceptable excipients for prevention, improvement, and maintenance of cognitive health to a subject in need thereof. The invention also discloses the process for preparing extracts from plant parts of Withania somnifera. The composition of the present invention is available in dosage forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms used for prevention, improvement and maintenance of cognitive health.
A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61P 43/00 - Drugs for specific purposes, not provided for in groups
The present invention relates to an oral berberis extract composition and the process for the preparation of the composition of berberis extract as whole or its salts and/or in combination with berberine, jatrorrhizine, and columbamine or its salts with at least one pharmaceutically and/or nutraceutically accepted excipients for prevention, improvement, and maintenance of cognitive health to a subject in need thereof. Further encompassing to the oral berberis composition wherein the berberis extract is comprised of berberis extract as whole or its salts and/or in combination with berberine and/or its salt, and optionally jatrorrhizine, and columbamine or its salts in different forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms. A method of use of the berberis extract composition for prevention, improvement, and maintenance of cognitive health.
A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present invention relates to an oral berberis extract composition and the process for the preparation of the composition of berberis extract as whole or its salts and/or in combination with berberine, jatrorrhizine, and columbamine or its salts with at least one pharmaceutically and/or nutraceutically accepted excipients for prevention, improvement, and maintenance of cognitive health to a subject in need thereof. Further encompassing to the oral berberis composition wherein the berberis extract is comprised of berberis extract as whole or its salts and/or in combination with berberine and/or its salt, and optionally jatrorrhizine, and columbamine or its salts in different forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms. A method of use of the berberis extract composition for prevention, improvement, and maintenance of cognitive health.
The present invention relates to a xanthophyll composition comprising selective isomers of trans-R,R lutein and trans-R,R zeaxanthin in preferred particle size and pharmaceutically and/or nutraceutically acceptable excipients such as carriers, solubility enhancers, bioavailability enhancing agents, antioxidants and optionally flavoring agents with selective ratio which exerts enhanced bioavailability. The xanthophyll composition at least 80% of total xanthophyll comprised of at least 65% by weight of trans-R,R lutein and at least 10% by weight of trans-R,R zeaxanthin, which is prepared combinedly from marigold and paprika oleoresins with definite proportion to produce the preferred ratio of trans-R,R lutein and trans-R,R zeaxanthin.
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention relates to a stable curcumin composition for prevention improvement and maintenance of arthritis more particularly to osteoarthritis. The stable curcumin composition is comprised of curcuminoids either alone or along with at least one pharmaceutically and/or nutraceutically accepted excipient to form the stable curcumin compositions having enhancement in absorption and bioavailability. The composition is safe for consumption, possess enhanced stability and bioavailability due to selective percentage of amorphous and crystalline polymorphic form of curcumin along with selective excipient such as pH modifier and/or stabilizer and optionally hydrophilic carrier, antioxidant, diluents, anticaking agent, emulsifier, fat and surfactant which result in improvement of symptoms of arthritis and associated conditions, when administered to subjects, in need thereof.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
The present invention is related to the valerian composition and /or valerian extract for prevention, improvement, and maintenance of sleep disorders and/or sleep management per se improve the quality sleep, improves time to sleep, improves sleep duration, reduces sleep disturbances, maintain healthy stress levels to a subject in need thereof. A valerian composition comprising of the valerian extract and at least one pharmaceutically and/or nutraceutically accepted excipients. The present invention further encompasses the valerian composition wherein further formulated in different forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms using pharmaceutically and/or nutraceutically acceptable excipients.
The present invention is related to the valerian composition and /or valerian extract for prevention, improvement, and maintenance of sleep disorders and/or sleep management per se improve the quality sleep, improves time to sleep, improves sleep duration, reduces sleep disturbances, maintain healthy stress levels to a subject in need thereof. A valerian composition comprising of the valerian extract and at least one pharmaceutically and/or nutraceutically accepted excipients. The present invention further encompasses the valerian composition wherein further formulated in different forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms using pharmaceutically and/or nutraceutically acceptable excipients.
A nutritional composition for prevention, improvement and maintenance of visual function. The nutritional composition comprising the nutrients and at least one pharmaceutically and/or nutraceutically accepted excipient. The nutritional composition wherein the nutrients are selected from one or more of lutein, curcumin and vitamin D3 for prevention, improvement and maintenance of dry eye. The process of preparation of the nutritional composition comprising lutein, curcumin and vitamin D3 use for visual function more specifically dry eye. The present invention is further encompassing to the nutritional composition comprising lutein, curcumin, vitamin D3 in selective percentage which is formulated in different forms like as, powders, granules, pellets, beadlets, caplets, tablets, capsules, soft gel capsules, solution, emulsions, suspensions, oil suspensions, dispersions and the like.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
The present invention describes pulsed release caffeine formulations comprising caffeine particulate systems prepared by using release retarding agents and at least one or more food grade excipients. The present invention also relates to the process for preparation of caffeine formulations, wherein plurality of particulate systems combined to get the pulsed release caffeine formulation comprising release retarding agents, which provide caffeine release in pulses at different physiological conditions. The pulsed release caffeine formulation is prepared as tablets, capsules, soft gel capsules, caplets, oil suspensions or mixed with nutrient supplements for administration to the subjects. Caffeine formulations as described herein release the caffeine over entire GIT in pulses in a period of 2 to 8 hours and can be administered to subjects for boosting energy, improving concentration, cardiovascular health and for weight management.
The present invention is related to the beta-cryptoxanthin composition comprising beta-cryptoxanthin with one and/or more pharmaceutically/ nutraceutically accepted excipient. More specifically the composition comprises beta-cryptoxanthin either alone or along with at least one carrier oil and antioxidant. The present invention is described the method for the prevention, improvement and/or maintenance of eye health by administering beta-cryptoxanthin compositions in an effective amount to a subject in need thereof. Methods are described herein that is related to prevention, improvement and/or maintenance of pre/age-related macular degeneration, diabetic retinopathy, retinal damage, eye strain & eye fatigue, vitamin A deficiency by administering a composition comprising beta-cryptoxanthin in effective amount either alone or along with at least one pharmaceutically and/or nutraceutically accepted excipient. The Beta-cryptoxanthin compositions described herein reduces retinal stress and inflammation to the subject in need thereof. The compositions herein are safe for human consumption and can be employed for management of overall eye health, when administered in an effective amount to the subject in need thereof.
The invention relates to a purified xanthophyll composition comprising (trans,R R)-lutein and (trans,R,R)-zeaxanthin, which is comprised of more than 80% of total xanthophylls and a process for the preparation thereof. Purified xanthophyll composition is comprised of selective isomers such as at least 85% by weight of (trans,R,R)-lutein and at least 15% by weight of (trans,R,R)-zeaxanthin. The composition is prepared by process of extraction from two different plant sources using industrially viable process and purified by employing food grade polar and non-polar solvents. The invention relates to purified xanthophyll composition which is selectively free from (R,S)-zeaxanthin and is suitable for human consumption.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products
The present invention relates to a stable curcumin composition for prevention improvement and maintenance of arthritis more particularly to osteoarthritis. The stable curcumin composition is comprised of curcuminoids either alone or along with at least one pharmaceutically and/or nutraceutically accepted excipient to form the stable curcumin compositions having enhancement in absorption and bioavailability. The composition is safe for consumption, possess enhanced stability and bioavailability due to selective percentage of amorphous and crystalline polymorphic form of curcumin along with selective excipient such as pH modifier and/or stabilizer and optionally hydrophilic carrier, antioxidant, diluents, anticaking agent, emulsifier, fat and surfactant which result in improvement of symptoms of arthritis and associated conditions, when administered to subjects, in need thereof.
A61K 36/9066 - Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A nutritional composition for prevention, improvement and maintenance of visual function. The nutritional composition comprising the nutrients and at least one pharmaceutically and/or nutraceutically accepted excipient. The nutritional composition wherein the nutrients are selected from one or more of lutein, curcumin and vitamin D3 for prevention, improvement and maintenance of dry eye. The process of preparation of the nutritional composition comprising lutein, curcumin and vitamin D3 use for visual function more specifically dry eye. The present invention is further encompassing to the nutritional composition comprising lutein, curcumin, vitamin D3 in selective percentage which is formulated in different forms like as, powders, granules, pellets, beadlets, caplets, tablets, capsules, soft gel capsules, solution, emulsions, suspensions, oil suspensions, dispersions and the like.
A nutritional composition for prevention, improvement and maintenance of visual function. The nutritional composition comprising the nutrients and at least one pharmaceutically and/or nutraceutically accepted excipient. The nutritional composition wherein the nutrients are selected from one or more of lutein, curcumin and vitamin D3 for prevention, improvement and maintenance of dry eye. The process of preparation of the nutritional composition comprising lutein, curcumin and vitamin D3 use for visual function more specifically dry eye. The present invention is further encompassing to the nutritional composition comprising lutein, curcumin, vitamin D3 in selective percentage which is formulated in different forms like as, powders, granules, pellets, beadlets, caplets, tablets, capsules, soft gel capsules, solution, emulsions, suspensions, oil suspensions, dispersions and the like.
The present invention encompasses an integrated actives selected from one or more of withanolide glycoside enriched ashwagandha, bisdemethoxycurcumin (BDMC) enriched curcumin and acetyl-11-keto-β-boswellic acid (AKBA) enriched boswellia or combination thereof use for prevention, improvement and maintenance of arthritis more specifically for osteoarthritis and joint wellness. Further the present invention is related to process of preparation of the integrated active composition. Further this composition comprises the selective ratio of integrated actives with at least one pharmaceutically and/or nutraceutically accepted excipient.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
The present invention relates to a xanthophyll composition comprising selective isomers of trans-R,R lutein and trans-R,R zeaxanthin in preferred particle size and pharmaceutically and/or nutraceutically acceptable excipients such as carriers, solubility enhancers, bioavailability enhancing agents, antioxidants and optionally flavoring agents with selective ratio which exerts enhanced bioavailability. The xanthophyll composition at least 80% of total xanthophyll comprised of at least 65% by weight of trans-R,R lutein and at least 10 % by weight of trans-R,R zeaxanthin, which is prepared combinedly from marigold and paprika oleoresins with definite proportion to produce the preferred ratio of trans-R,R lutein and trans-R,R zeaxanthin.
The present invention relates to a xanthophyll composition comprising selective isomers of trans-R,R lutein and trans-R,R zeaxanthin in preferred particle size and pharmaceutically and/or nutraceutically acceptable excipients such as carriers, solubility enhancers, bioavailability enhancing agents, antioxidants and optionally flavoring agents with selective ratio which exerts enhanced bioavailability. The xanthophyll composition at least 80% of total xanthophyll comprised of at least 65% by weight of trans-R,R lutein and at least 10 % by weight of trans-R,R zeaxanthin, which is prepared combinedly from marigold and paprika oleoresins with definite proportion to produce the preferred ratio of trans-R,R lutein and trans-R,R zeaxanthin.
The present invention describes pulsed release caffeine formulations comprising caffeine particulate systems prepared by using release retarding agents and at least one or more food grade excipients. The present invention also relates to the process for preparation of caffeine formulations, wherein plurality of particulate systems combined to get the pulsed release caffeine formulation comprising release retarding agents, which provide caffeine release in pulses at different physiological conditions. The pulsed release caffeine formulation is prepared as tablets, capsules, soft gel capsules, caplets, oil suspensions or mixed with nutrient supplements for administration to the subjects. Caffeine formulations as described herein release the caffeine over entire GIT in pulses in a period of 2 to 8 hours and can be administered to subjects for boosting energy, improving concentration, cardiovascular health and for weight management.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products
36.
PURIFIED XANTHOPHYLL COMPOSITION COMPRISING (TRANS,R,R)- LUTEIN AND(TRANS,R,R)- ZEAXANTHIN AND PROCESS FOR THE PREPARATION THEREOF
The invention relates to a purified xanthophyll composition comprising (trans,R R)-lutein and (trans,R,R)-zeaxanthin, which is comprised of more than 80% of total xanthophylls and a process for the preparation thereof. Purified xanthophyll composition is comprised of selective isomers such as at least 85% by weight of (trans,R,R)-lutein and at least 15% by weight of (trans,R,R)- zeaxanthin. The composition is prepared by process of extraction from two different plant sources using industrially viable process and purified by employing food grade polar and non-polar solvents. The invention relates to purified xanthophyll composition which is selectively free from (R,S)- zeaxanthin and is suitable for human consumption.
C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
37.
PURIFIED XANTHOPHYLL COMPOSITION COMPRISING (TRANS,R,R)- LUTEIN AND(TRANS,R,R)- ZEAXANTHIN AND PROCESS FOR THE PREPARATION THEREOF
The invention relates to a purified xanthophyll composition comprising (trans,R R)-lutein and (trans,R,R)-zeaxanthin, which is comprised of more than 80% of total xanthophylls and a process for the preparation thereof. Purified xanthophyll composition is comprised of selective isomers such as at least 85% by weight of (trans,R,R)-lutein and at least 15% by weight of (trans,R,R)- zeaxanthin. The composition is prepared by process of extraction from two different plant sources using industrially viable process and purified by employing food grade polar and non-polar solvents. The invention relates to purified xanthophyll composition which is selectively free from (R,S)- zeaxanthin and is suitable for human consumption.
C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
FOOD GRADE EXCIPIENTS, ANTIOXIDANTS, AND PLANTS EXTRACTS USED AS AN INGREDIENT AND COMPONENT PART IN THE MANUFACTURE OF NUTRITIONAL AND DIETARY SUPPLEMENTS
40.
Methods for improving physical performance and capsicum compositions used therein
capsicum composition to a physically active subject, wherein body antioxidants are increased and muscle lactates are decreased, resulting in recovery from muscle fatigue arising due to such indoor and/or outdoor physical activities.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
PLANTS EXTRACTS SOLD AS AN INGREDIENT IN OR COMPONENT PART OF NUTRITIONAL AND DIETARY SUPPLEMENTS, MEDICINAL FUNCTIONAL FOODS AND BEVERAGES AND MEDICAL FOODS; NUTRITIONAL SUPPLEMENTS
42.
Stabilized fat soluble nutrient compositions and process for the preparation thereof
A stabilized composition of fat soluble nutrient(s) includes a water soluble polymer and at least one nutraceutically acceptable excipient. The composition can be in the form of significantly amorphous aqueous microparticulate mixtures or as a solid beadlet product. A process for preparation of a stabilized composition includes a fat soluble nutrient solubilized in an organic solvent embedded in an aqueous polymer phase by evaporation, so as to obtain an aqueous microparticulate mixture. This mixture is stable, soluble and can be formulated for end use or can be layered on inert core for example to obtain stable beadlet(s) for use in solid dosage forms. Such stabilized aqueous microparticulate and solid beadlet compositions exhibit good solubility and dispersibility. Stabilized compositions of fat soluble nutrients can be prepared using industrially convenient equipment and can be formulated as per requirement for use in health applications.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plants extracts sold as an ingredient in or component part of nutritional and dietary supplements, medicinal functional foods and beverages and medical foods
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products Food flavorings in the form of plant extracts containing lutein and zeaxanthin and not being essential oils for dietary, nutritional and health food applications, not including eye-related or ophthalmic products
46.
IMPROVING PHYSICAL PERFORMANCE WITH CAPSICUM COMPOSITIONS
Methods of improving physical performance and endurance include administering a capsicum composition to a subject. More particularly the methods include administration of an effective amount of a capsicum composition including capsaicinoids alone and/or in combination with other nutrients for improvement in performance of physical activities. The methods described include administration of a capsicum composition to a subject undergoing physical activity to deliver daily dose of capsaicinoids in an effective amount. The methods include administering a capsicum composition to a subject in an effective amount to reduce blood lipids and oxidative stress. Methods for enhancing physical endurance and exhaustion time include administering an effective amount of a capsicum composition to a physically active subject, wherein body antioxidants are increased and muscle lactates are decreased, resulting in recovery from muscle fatigue arising due to such indoor and/or outdoor physical activities.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plant extracts used as an ingredient in or component part of nutritional and dietary supplements, medicinal functional foods and beverages and medical foods.
48.
METHOD FOR TREATMENT OF VISUAL STRESS CONDITIONS AND COMPOSITIONS USED THEREIN
The methods relate to preventing photoreceptor damage caused by blue light by oral administration of a macular carotenoid composition comprising of lutein and zeaxanthin isomers. The photoreceptor damage is prevented through the upregulation of genes and protein synthesis manifested by an increase in the levels gene expression and proteins synthesis of Gnatl, Rhodopsin, NCAM, Rod arrestin, GAP-43, Nrf2, Ho-1 and decrease in the GFAP, NFkB (oxidative stress markers) in rat eye models exposed to visible blue light for various time periods and simultaneously treated with macular carotenoid compositions comprising of lutein zeaxanthin and their isomers. Methods described herein also relate to treatment of visual stress conditions by administering macular carotenoid compositions for treatment headache, blurred vision, photoreceptor degeneration, oxidative stress, endoplasmic reticulum stress and the like, which are caused due to prolonged exposure to blue light source.
The invention relates to compositions comprising lipophilic active, effective amount of an absorption augmenting agent and suitable excipients and the process for preparation thereof. More particularly, the fine free flowing powder composition described herein is comprised of effective amount of lipophilic active such as coenzyme Q10, absorption augmenting agent and other suitable excipients which is formulated by emulsification and size reduction. The size reduced emulsion is spray dried to get fine free flowing powder of lipophilic active which may be further filled in sachets or formulated into solid dosage forms or suspended in oil medium. Oil suspension can be encapsulated in soft gel capsules and/or filled in sachets and is useful for treatment of health ailments. Use of salacia as absorption augmenting agent in coenzyme Q10 formulation resulted in more than 2 times enhanced bioavailability in aqueous medium as compared to unformulated coenzyme Q10.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
A61K 36/37 - Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
05 - Pharmaceutical, veterinary and sanitary products
31 - Agricultural products; live animals
Goods & Services
(1) Food grade antioxidants and plant extracts, namely, curcumin, sold together as a unit with excipients, used as ingredients in or component part of nutritional and dietary supplements
Curcumin compositions are described for administration to healthy subjects, in need thereof, for improving cardiovascular flow. Curcumin compositions described herein can be administered to a subject in an effective dose of 250 mg to 1000 mg, corresponding to about 50 mg to 200 mg curcuminoids, for improvement of endothelial function and reducing risk of cardiovascular diseases. Compositions herein include curcumin either alone or curcumin along with at least one excipient to enhance absorption. Compositions herein improve endothelial function in healthy subjects having FMD value of 5-7% or higher and who are not diagnosed with cardiovascular disease. Compositions herein also improve cardiovascular endothelial function by reducing vascular resistance and enhancing nitric oxide generation in vascular endothelium. Curcumin compositions herein are safe for consumption, possesses enhanced absorption and can be employed for improvement of endothelial function and cardiovascular flow, when administered in an effective dose to a healthy subject, in need thereof.
Xanthophyll compositions and their methods of use are described, where the compositions include macular pigments as lutein and/or zeaxanthin isomers, and where they are administered in an effective amount for skin lightening and/or improving overall skin tone and/or health in a subject in need thereof. Methods for treatment are described for improvement and/or protection of skin from effects of light rays of variable intensity and/or wavelength on skin tone and/or skin health. Methods herein include administering a xanthophyll composition for skin lightening and/or improving skin tone and/or overall skin health, and to block the melanin pathway and formation of melanin in melanocytes. The compositions and their administration exhibit increased Individual Typological Angle and minimum erythemal dose, which results in rapid skin lightening. The compositions improve overall skin tone and/or skin health, when administered in an effective amount by improving hydration, flexibility and/or protecting skin from damaging effects of light radiation.
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
(1) Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements and dietary supplements for general health and well-being, excluding eye-related or ophthalmic products
(2) Food flavorings in the form of plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements and dietary supplements for general health and well-being, excluding eye-related or ophthalmic products
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Plant extracts used as an ingredient in or component part of nutritional and dietary supplements, medicinal functional foods and beverages and medical foods for general health and well-being
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Plants extracts used as an ingredient in or component part of nutritional and dietary supplements, functional foods and beverages and medical foods for general health and well-being
Capsicum compositions are described that include biologically active constituents non- capsaicinoids and capsaicinoids in a specific ratio are useful for the treatment and management of cardiometabolic syndrome and associated risk factors, in a subject in need thereof. The capsicum compositions include a capsicum extract which is prepared by extracting capsicum pods by using suitable polar and non-polar solvents. Capsicum compositions include non- capsaicinoid components like saponins and polyphenols such as flavonoids, which along with capsaicinoids effectively reduce risk factors of cardiometabolic syndrome and also reduce oxidative stress on vital body organs by reducing inflammatory and/or oxidative markers. The capsicum compositions inhibit pancreatic lipase enzyme and enhance lipolysis, when administered in an effective amount to a subject in need thereof. Capsicum compositions as described herein are prepared by human intervention and are safe for consumption.
Compositions are described that include a betacryptoxanthin extract, rich in trans-betacryptoxanthin, which are prepared by a cost and time effective process and are for use in methods of enhancing cardio-respiratory fitness for physical performance and exercise endurance and to maintain healthy lung function. Betacryptoxanthin extract is prepared by a cost and time effective process of saponification and column chromatography, in which saponification cycle time, solvent amount, column separation time and silica amount are reduced, thus making it industrially viable. Betacryptoxanthin compositions increase exercise time, endurance performance, and lung capacity and maintain healthy lung and cardiovascular function during such physical activities. The compositions also improve physical performance, attenuate muscle fatigue, and enhance aerobic respiration utilization capacity. The compositions are safe for consumption, and can be employed for enhancing cardio-respiratory fitness when administered in an effective amount.
A01N 43/04 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom
A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
Beta-cryptoxanthin compositions and methods are described for the management of cardiometabolic syndrome and associated risk factors, in a subject, in need thereof. Methods herein are directed to identifying such subject at risk of developing cardiometabolic syndrome and administering beta-cryptoxanthin composition to assess the condition of an organ. Compositions and methods herein can effectively reduce risk factors of cardiometabolic syndrome, such as hyperlipidemia, insulin resistance, obesity, diabetes, atherosclerosis and/or related cardiovascular disorders. Beta-cryptoxanthin compositions and methods herein can reduce body weight, body fat, glucose levels, and free fatty acids, when administered in effective amounts. The compositions and methods herein can also reduce oxidative stress on organs such as the eye and liver and/or reduce inflammatory and/or oxidative markers, when administered to subjects in need thereof.
Methods herein are described for improvement in visual function by administering macular carotenoid compositions containing an effective daily dose, to a subject in need thereof. More particularly, methods herein are described and include use of the compositions herein by identifying a subject in need thereof, administering a daily dose of lutein and/or zeaxanthin isomers, comprised of meso-zeaxanthin and R,R zeaxanthin, alone or in combination thereof, the composition also including at least one food grade excipient, and evaluating visual performance. The subject is exposed to light of variable wavelengths and intensity and is suffering from visual fatigue. The composition improves contrast sensitivity, glare performance, photo stress recovery, and/or macular pigment optical density, and thus alleviates visual fatigue. The composition is safe for human and other animals for consumption and can be used for improvement in visual health in the subject, when administered in an effective amount.
Methods herein are described for improvement in visual function by administering macular carotenoid compositions containing an effective daily dose, to a subject in need thereof. More particularly, methods herein are described and include use of the compositions herein by identifying a subject in need thereof, administering a daily dose of lutein and/or zeaxanthin isomers, comprised of meso-zeaxanthin and R,R zeaxanthin, alone or in combination thereof, the composition also including at least one food grade excipient, and evaluating visual performance. The subject is exposed to light of variable wavelengths and intensity and is suffering from visual fatigue. The composition improves contrast sensitivity, glare performance, photo stress recovery, and/or macular pigment optical density, and thus alleviates visual fatigue. The composition is safe for human and other animals for consumption and can be used for improvement in visual health in the subject, when administered in an effective amount.
A01N 65/00 - Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
C07C 403/00 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone
64.
METHOD FOR PROTECTION AND IMPROVEMENT OF LIVER HEALTH WITH MESO-ZEAXANTHIN COMPOSITIONS
A method for protection, treatment and improvement of liver health includes administering a meso-zeaxanthin composition in an effective amount to a subject in need thereof. In particular, methods are described of administering a meso-zexanthin composition to a subject fed with high fat diet (HFD), and studying the effect of meso-zeaxanthin for treatment of fatty liver condition, through evaluation of various parameters such as biochemical indicators, anti-inflammatory markers, and nutritional markers.
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Carotenoid compositions are described for management, treatment, and/or prevention of stress by reducing cortisol levels and/or improving distribution and/or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005mg/kg body weight of lutein, and at least or about 0.001mg/kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and/or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.
A61K 31/047 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07C 35/21 - Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a non-condensed ring
66.
Method for stress management and overall health status improvement and compositions used therein
Carotenoid compositions are described for management, treatment, and/or prevention of stress by reducing cortisol levels and/or improving distribution and/or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005 mg/kg body weight of lutein, and at least or about 0.001 mg/kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and/or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.
G01N 33/74 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving hormones
G01N 33/487 - Physical analysis of biological material of liquid biological material
G01N 30/00 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography
A method for protection, treatment and improvement of liver health includes administering a meso-zeaxanthin composition in an effective amount to a subject in need thereof. In particular, methods are described of administering a meso-zexanthin composition to a subject fed with high fat diet (HFD), and studying the effect of meso-zeaxanthin for treatment of fatty liver condition, through evaluation of various parameters such as biochemical indicators, anti-inflammatory markers, and nutritional markers.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Plants extracts, namely mustard oil extract sold as an ingredient in or component part of nutritional and dietary supplements, medicinal functional foods and beverages and medical foods; nutritional supplements.
69.
STABLE OIL SUSPENSIONS COMPRISING LIPOPHILIC NUTRIENT WITH ENHANCED BIOAVAILABILITY AND PROCESS OF PREPARATION
Stable oil suspensions are described that have enhanced bioavailability and contain lipophilic nutrients uniformly dispersed in a solid hydrophilic carrier and suspended in an oil medium. A process for preparation of stable oil suspensions of lipophilic nutrients and compositions of these suspensions such as soft gelatin capsules are also described. The oil suspensions include soluble granules of lipophilic nutrients suspended in oil. Soluble granules include lipophilic nutrients dispersed uniformly in a solid hydrophilic carrier with one or more food grade excipient. Stable oil suspensions of the invention include at least 1% to about 50% lipophilic nutrient. These oil suspensions are resistant to oxidation and exhibit enhanced stability and bioavailability as compared to soluble granules and to marketed comparative products. Oil suspensions herein can be encapsulated in soft gel capsules or filled in sachets to administer conveniently to patients.
The present invention provides use of composition containing molecular dispersions of carotenoids for the prevention of neurodegenerative disorders which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits. The present invention particularly relates to the use of highly water soluble composition with enhanced bioavailability containing at least 80% by weight of total xanthophylls, out of which the trans-lutein content is 80-95% w/w; (R,R)-zeaxanthin is 14-20% w/w; (R,S)-zeaxanthin is 0.01-1% w/w and traces of other carotenoids derived from the plant extracts/oleoresin containing xanthophylls/xanthophylls esters. The present invention also provides use of the said composition in treatment of neurodegenerative disorders when co-administered along with reduced dose of Levodopa and Carbidopa.
capsicum fruits. The production of beta-cryptoxanthin crystals with high content of trans-beta-cryptoxanthin makes it ideal and suitable for use as a provitamin A source material and also has potential effects on improving bone health and inhibiting bone resorption.
A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
C07C 403/02 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains containing only carbon and hydrogen atoms
A61K 31/045 - Hydroxy compounds, e.g. alcoholsSalts thereof, e.g. alcoholates
C07C 403/24 - Derivatives of cyclohexane or of a cyclohexene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by six-membered non-aromatic rings, e.g. beta-carotene
C09B 61/00 - Dyes of natural origin prepared from natural sources
B01D 15/42 - Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
A23L 5/44 - Addition of dyes or pigments, e.g. in combination with optical brighteners using naturally occurring organic dyes or pigments, their artificial duplicates or their derivatives using carotenoids or xanthophylls
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
72.
Hydrophilic matrix beadlet compositions with enhanced bioavailability
The instant invention provides hydrophilic matrix beadlet compositions that include at least one fat soluble nutrient and an effective amount of cellulose polymer with low viscosity. The invention also provides a process for the preparation of the hydrophilic matrix composition by employing a fluid bed system or extrusion spheronization technique. This hydrophilic matrix beadlet composition is comprised of at least 5% to about 25% carotenoid wherein free lutein is present in combination with zeaxanthin. The free flowing nature of the composition allows it to be compressed into tablets or to be filled into two piece capsules or blended as a dry premix for beverage applications. These hydrophilic matrix compositions exhibit desired dissolution characteristics and at least 1.6 times more bioavailability as compared with marketed reference formulations containing modified starch, thus making it advantageous for nutraceutical applications.
The instant invention provides hydrophilic matrix beadlet compositions that include at least one fat soluble nutrient and an effective amount of cellulose polymer with low viscosity. The invention also provides a process for the preparation of the hydrophilic matrix composition by employing a fluid bed system or extrusion spheronization technique. This hydrophilic matrix beadlet composition is comprised of at least 5% to about 25% carotenoid wherein free lutein is present in combination with zeaxanthin. The free flowing nature of the composition allows it to be compressed into tablets or to be filled into two piece capsules or blended as a dry premix for beverage applications. These hydrophilic matrix compositions exhibit desired dissolution characteristics and at least 1.6 times more bioavailability as compared with marketed reference formulations containing modified starch, thus making it advantageous for nutraceutical applications.
Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic methods using conventional equipments and can be effectively used for enhancing muscle and exercise performance.
Curcumin compositions herein are described for improving muscle performance, endurance capacity and resistance to fatigue, when administered in effective amounts to a subject in need of such improvement. The compositions are comprised of curcumin and at least one pharmaceutically and/or nutraceutically acceptable excipient such as a hydrophilic carrier and exhibit enhanced bioavailability. More particularly methods are described and include use of curcumin compositions to increase exercise time, performance and capacity and to prevent muscle soreness, fatigue and injury. The compositions enhance mitochondrial biogenesis by modulating mitochondrial function, increasing mitochondrial mass and oxygen consumption, thus increasing mitochondrial aerobic capacity. The compositions reduce oxidative muscle stress, by decreasing inflammatory cytokines and inflammatory markers. Curcumin compositions are safe for consumption for pharmaceutical and/or nutraceutical purposes and are prepared by economic methods using conventional equipments and can be effectively used for enhancing muscle and exercise performance.
Compositions containing molecular dispersions of lipophilic nutrients and methods thereof are provided for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, methods relate to delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, turmeric extract, curcumin or curcuminoids, derived from plant extract/oleoresin containing xanthophylls/xanthophylls esters which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits.
A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
A61K 31/09 - Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
A composition of oily, pungent and odoriferous substances and a process for preparation thereof are described, in particular an extended and sustained release of a stable, free flowing, solid composition of one or more of substances such as capsicum, black pepper, ginger, mustard, cinnamon, garlic, onion, paprika, turmeric and the like, extracts thereof, and/or components thereof, and a process for preparation thereof are described. For example, compositions comprise a substance such as capsicum containing capsaicinoid components, which include for example capsaicin, dihydro-capsaicin, and/or nor-dihydro-capsaicin.The composition can eliminate the discomfort by facilitating intestinal absorption of the active ingredient and thereby minimizing/eliminating the discomfort caused by the residual unabsorbed active ingredient, and can be particularly suitable for formulating into consumable dry syrups, tablets, capsules, liquid syrups, health drinks, diet drinks, fruit juices, and/or soft drinks, which can be useful in reduction of body weight.
capsicum containing capsaicinoid components, which include for example capsaicin, dihydro-capsaicin, and/or nor-dihydro-capsaicin. The composition can eliminate the discomfort by facilitating intestinal absorption of the active ingredient and thereby minimizing/eliminating the discomfort caused by the residual unabsorbed active ingredient, and can be particularly suitable for formulating into consumable dry syrups, tablets, capsules, liquid syrups, health drinks, diet drinks, fruit juices, and/or soft drinks, which can be useful in reduction of body weight.
A61K 36/81 - Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
A23L 33/125 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing carbohydrate syrupsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugarsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing sugar alcoholsModifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives containing starch hydrolysates
A23L 5/00 - Preparation or treatment of foods or foodstuffs, in generalFood or foodstuffs obtained therebyMaterials therefor
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A23P 10/30 - Encapsulation of particles, e.g. foodstuff additives
A23L 27/00 - SpicesFlavouring agents or condimentsArtificial sweetening agentsTable saltsDietetic salt substitutesPreparation or treatment thereof
A23L 27/10 - Natural spices, flavouring agents or condimentsExtracts thereof
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
A23L 29/30 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing carbohydrate syrupsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugarsFoods or foodstuffs containing additivesPreparation or treatment thereof containing sugar alcohols, e.g. xylitolFoods or foodstuffs containing additivesPreparation or treatment thereof containing starch hydrolysates, e.g. dextrin
A23L 29/262 - CelluloseDerivatives thereof, e.g. ethers
Salacia compositions herein reduce appetite by about 18% of routine diet, when effective amounts are administered to a subject in need thereof. Effective management of a healthy lipid profile is thus possible with synergistic combination of reduction in energy intake, activation of Hormone Sensitive Lipase, and inhibition of HMG-CoA Reductase enzyme responsible for cholesterol metabolism.
A61K 36/37 - Celastraceae (Staff-tree or Bittersweet family), e.g. tripterygium or spindletree
A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products. Food flavorings in the form of plant extracts containing lutein and zeaxanthin and not being essential oils for dietary, nutritional and health food applications, not including eye-related or ophthalmic products.
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
Plant extracts sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products. Food flavorings in the form of plant extracts and not being essential oils for dietary, nutritional and health food applications, not including eye-related or ophthalmic products.
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
Plant extracts sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products. Food flavorings in the form of plant extracts and not being essential oils for dietary, nutritional and health food applications, not including eye-related or ophthalmic products.
The present invention provides use of composition containing molecular dispersions - of carotenoids for the prevention of neurodegenerative disorders which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits. The present invention particularly relates to the use of highly water soluble composition with enhanced bioavailability containing at least 80% by weight of total xanthophylls, out of which the trans-lutein content is 80-95% w/w; (R,R)-zeaxanthin is 14-20% w/w; (R,S)-zeaxanthin is 0.01-1%) w/w and traces of other carotenoids derived from the plant extracts/oleoresin containing xanthophylls/xanthophylls esters. The present invention also provides use of the said composition in treatment of neurodegenerative disorders when co-administered along with reduced dose of Levodopa and Carbidopa.
The present invention provides beta-cryptoxanthin crystals from plant source and a process for its preparation. The present invention particularly relates to a process for the preparation of high purity beta-cryptoxanthin crystals comprising at least about 10% by weight total xanthophylls, of which at least about 75% by weight is trans-beta-cryptoxanthin and the remaining including beta-carotene, and trace amounts of trans-capsanthin and other carotenoids derived from the plant source, including capsicum fruits. The production of beta-cryptoxanthin crystals with high content of trans-beta-cryptoxanthin makes it ideal and suitable for use as a provitamin A source material and also has potential effects on improving bone health and inhibiting bone resorption.
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
(1) Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements and dietary supplements for general health and well-being, not including eye-related or ophthalmic products; flavorings in the form of plant extracts containing lutein and zeaxanthin and not being essential oils for dietary, nutritional and health food applications, not including eye-related or ophthalmic products.
05 - Pharmaceutical, veterinary and sanitary products
30 - Basic staples, tea, coffee, baked goods and confectionery
Goods & Services
Plant extracts containing lutein and zeaxanthin sold as an integral component of nutritional supplements for dietary and health applications, not including eye-related or ophthalmic products Flavorings in the form of plant extracts containing lutein and zeaxanthin and not being essential oils for dietary, nutritional and health food applications, not including eye-related or ophthalmic products
01 - Chemical and biological materials for industrial, scientific and agricultural use
Goods & Services
(1) Omega 3 fatty acids and plant extracts, namely, lutein extracts for use as an ingredient in the manufacture of dietary and nutritional supplements.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Plant extract used as a component ingredient of dietary supplements and nutritional supplements for general health and well-being; nutritional and dietary supplements for general health and well-being.
The present invention provides a process for the preparation of lycopene containing oleoresin and lycopene crystals for human consumption. The present invention provides an efficient process for the preparation of lycopene crystals from lycopene containing oleoresin with at least 85% by weight lycopene, containing at least 90% by weight trans-lycopene and trace amounts of cis-lycopene and other carotenoids. The production of commercial grade lycopene crystals with high content of trans- lycopene makes it ideal and suitable for human consumption, use as an anti-oxidant, for applications in prevention of cancer and macular degenerative diseases, as an anti-oxidant, and as a food/feed colorant. The process is simple, convenient, economical and commercially feasible.
The invention disclosed relates to a water-soluble composition having enhanced bioavailability useful for the treatment of depression which comprises a synergistic combination of curcumin, at least an antioxidant, a hydrophilic carrier and a fat. The invention also discloses a process for the preparation of the curcumin composition which comprises the steps of dissolving curcumin, at least one antioxidant, a hydrophilic carrier and a fat in a solvent to form a homogenous mass; warming the resultant mass at a temperature ranging from 25°C to 60°C for a period of 4 to 8 hours to obtain a dry wet mass; removing the solvent by evaporation to form dry mass and pulverizing the dry mass to form a fine powder.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
